Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL

Publish date:: December 9, 2019

Key clinical point: The study was halted early because of short-lived response and disease hyperprogression.

Major finding: Median progression-free survival was 2.7 months, and median overall survival was 6.7 months

Study details: An interim analysis of a phase 2 trial with 12 patients with peripheral T-cell lymphomas.

Disclosures: The study was supported by Bristol-Myers Squibb. Dr. Bennani reported research funding and advisory board activities for Bristol-Myers Squibb and others.

Citation:

Bennani NN et al. ASCO 2019, Abstract 467.

This Week's Must Reads

Consider potential cognitive complications prior to androgen deprivation therapy,

Diabetes raises risk of prostate cancer mortality in obese men,

Salivation inhibition fails to reduce radioiodine toxicity in prostate cancer,

Highest positive surgical margin predicts poor survival after prostatectomy,

Young minority men are underinformed about prostate cancer screening,

Must Reads in Oncology

Surgery improves survival in localized prostate cancer,

Ten-Year Results Support Partial Breast Irradiation,

Tucatinib Called Game-Changer in HER2-Positive Metastatic Breast Cancer,

Study Halted; ‘Hyperprogression’ Seen With Nivolumab for R/R PTCL,

Bispecific CAR T-Cells Yield High Response Rate in Relapsed/Refractory Myeloma,